Superworth

Monte Rosa Therapeutics profit margin GLUE

Gross, operating and net profit as a share of revenue over the last twelve months, from 2024.

Net margin, 12 months
n/m
not a meaningful number
Peer median
23.5%

Monte Rosa Therapeutics' net margin works out at −561% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−31.2%−43.8%
FY2024−96.1%n/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25−31.2%+64.9 pts−43.8%
Q3 FY2511.5%n/a4.7%
Q2 FY2513.6%n/a8.4%
Q1 FY253.9%n/a−1.3%
Q4 FY24−96.1%n/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Biotechnology nearest Monte Rosa Therapeutics' size, closest first, today.

CompanyProfit margin
GLUEMonte Rosa Therapeuticsn/m
MGTXMeiraGTx19.9%
VCELVericel7.9%
ADMAAdma Biologics33.0%
PLXProtalix BioTherapeutics23.5%
KRYSKrystal Biotech54.8%
Peer median23.5%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Monte Rosa Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.